While researchers and drug developers have made several efforts to develop effective treatments for glioblastoma (GBM), the standard of care (SoC) has remained stagnant in this indication for years due to its aggressiveness and the difficulty in getting therapies past the blood-brain barrier.
However, some new approaches are currently in varying stages of development in this aggressive form of brain cancer, which could see the treatment paradigm shift for the first time in decades.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In this episode of the GlobalData Healthcare podcast, Medical Device Network reporter Annabel Kartal-Allen speaks with Richard Wakefield, founder and CEO of European medtech company CureGBM, about the potential of a new type of non-invasive therapy for GBM called sonodynamic therapy.
He talks through the company’s efforts to support early European clinical trials exploring sonodynamic therapy’s potential role in GBM treatment, while sharing the inspiring story behind CureGBM as a company.
If you liked this episode of the GlobalData Healthcare podcast, make sure to check out our Spotify page at this link, where you can find several episodes diving into the wonderful world of pharma, biotech, medtech and clinical trials.
There have also been exciting new developments for the podcast, as we are now switching to a weekly upload schedule, meaning you can catch up with the biggest talking points across healthcare every Thursday!
